On June 26, 2015 Provectus Biopharmaceuticals reported that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, FL, USA) presented data on "Intralesional Therapy for Melanoma with PV-10" during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany (Press release, Provectus Pharmaceuticals, JUN 26, 2015, http://www.pvct.com/pressrelease.html?article=20150626.1 [SID:1234505810]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sondak spoke during "Symposium III – New Drugs and Trials I: Immunotherapy," held Thursday, June 25. His conclusions included that "among the many agents currently being evaluated for use as intralesional therapy for melanoma, PV-10 possesses favorable safety and handling properties and induces rapid ablation of injected lesions to a degree similar to or possibly better than other agents," and "preclinical and clinical data suggest PV-10 would be a good candidate to evaluate in conjunction with available systemic immunotherapies."

The complete presentation is available at http://www.pvct.com/publications/Post-Chicago-Munich-Sondak-2015.pdf.

In addition, the poster titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma," which details the Company’s phase 3 clinical trial that began recently, was also presented at the meeting. For the poster, visit http://pvct.com/publications/Post-Chicago-Munich-2015.pdf.